Neoadjuvant erlotinib and surgical resection of a stage iiia papillary adenocarcinoma of the lung with an L861Q activating EGFR mutation.
about
Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q.Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC.Use of a tyrosine kinase inhibitor as neoadjuvant therapy for non-small cell lung cancer: A case report.Eventual role of EGFR-tyrosine kinase inhibitors in early-stage non-small-cell lung cancer.[Analyzing the Sensitivity of EGFR-L861Q Mutation to TKIs and A Case Report].Surgical resection of advanced non-small cell lung cancer after a response to EGFR-TKI: presentation of two cases and a literature review.
P2860
Neoadjuvant erlotinib and surgical resection of a stage iiia papillary adenocarcinoma of the lung with an L861Q activating EGFR mutation.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Neoadjuvant erlotinib and surg ...... 861Q activating EGFR mutation.
@ast
Neoadjuvant erlotinib and surg ...... 861Q activating EGFR mutation.
@en
type
label
Neoadjuvant erlotinib and surg ...... 861Q activating EGFR mutation.
@ast
Neoadjuvant erlotinib and surg ...... 861Q activating EGFR mutation.
@en
prefLabel
Neoadjuvant erlotinib and surg ...... 861Q activating EGFR mutation.
@ast
Neoadjuvant erlotinib and surg ...... 861Q activating EGFR mutation.
@en
P2860
P356
P1433
P1476
Neoadjuvant erlotinib and surg ...... 861Q activating EGFR mutation.
@en
P2093
P2860
P304
P356
10.3747/CO.19.908
P577
2012-06-01T00:00:00Z